Literature DB >> 3922897

Epidemic outbreak of non-A, non-B hepatitis in a plasmapheresis center. II: Clinical observations and a four-year follow-up of patients.

N Muss, G G Frösner, F Sandhofer.   

Abstract

An epidemic outbreak of non-A, non-B hepatitis occurred in 1977/78 involving 30 donors at a plasmapheresis center. Of 27 hospitalized patients with peak ALT values between 334 and 1736 (mean 831) IU/l, only 16 had subjective symptoms like fatigue and lack of appetite, 11 had nausea, 11 were jaundiced and one developed transient arthritis. Patients with jaundice became chronically ill significantly less frequently than those without jaundice. Nineteen of 26 patients followed up had elevated ALT values after 12 months (73%) and 11 after 46 months (42%). Needle liver biopsies performed in 18 of the 19 patients with elevated ALT after 12 months revealed chronic persistent hepatitis in 14 and chronic active hepatitis in three. Follow-up biopsies always showed improvement (nine patients) or complete recovery (eight patients).

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3922897     DOI: 10.1007/bf01660415

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  10 in total

1.  A classification of chronic hepatitis.

Authors:  J De Groote; V J Desmet; P Gedigk; G Korb; H Popper; H Poulsen; P J Scheuer; M Schmid; H Thaler; E Uehlinger
Journal:  Lancet       Date:  1968-09-14       Impact factor: 79.321

2.  Epidemic outbreak of non-A, non-B hepatitis in a plasmapheresis center. I: Epidemiological observations.

Authors:  N Muss; G G Frösner; F Sandhofer
Journal:  Infection       Date:  1985 Mar-Apr       Impact factor: 3.553

3.  Clinical, epidemiological and prognostic aspects of hepatitis A, B and "non-A, non-B".

Authors:  G Norkrans
Journal:  Scand J Infect Dis Suppl       Date:  1978

4.  Chronic non-A, non-B hepatitis carrier state: transmissible agent documented in one patient over a six-year period.

Authors:  E Tabor; L B Seeff; R J Gerety
Journal:  N Engl J Med       Date:  1980-07-17       Impact factor: 91.245

5.  [Epidemiology and prognosis of non-A, non-B hepatitis (author's transl)].

Authors:  R Müller; H Willers; K W Knocke; S Sipos; W Höpken
Journal:  Dtsch Med Wochenschr       Date:  1979-10-19       Impact factor: 0.628

Review 6.  A randomized, double blind controlled trial of the efficacy of immune serum globulin for the prevention of post-transfusion hepatitis. A Veterans Administration cooperative study.

Authors:  L B Seeff; H J Zimmerman; E C Wright; J D Finkelstein; P Garcia-Pont; H B Greenlee; A A Dietz; C M Leevy; C H Tamburro; E R Schiff; E M Schimmel; R Zemel; D S Zimmon; R W McCollum
Journal:  Gastroenterology       Date:  1977-01       Impact factor: 22.682

7.  Clinical and serological analysis of transfusion-associated hepatitis.

Authors:  H J Alter; P V Holland; A G Morrow; R H Purcell; S M Feinstone; Y Moritsugu
Journal:  Lancet       Date:  1975-11-01       Impact factor: 79.321

8.  Non-B hepatitis in Japanese recipients of blood transfusions: clinical and serologic studies after the introduction of laboratory screening of donor blood for hepatitis B surface antigen.

Authors:  A Tateda; K Kikuchi; Y Numazaki; R Shirachi; N Ishida
Journal:  J Infect Dis       Date:  1979-05       Impact factor: 5.226

9.  Non-A non-B hepatitis associated with chronic liver disease in a haemodialysis unit.

Authors:  R M Galbraith; J L Dienstag; R H Purcell; P H Gower; A J Zuckerman; R Williams
Journal:  Lancet       Date:  1979-05-05       Impact factor: 79.321

10.  Development of chronic liver disease after acute non-A, non-B post-transfusion hepatitis. Role of gamma-globulin prophylaxis in its prevention.

Authors:  R G Knodell; M E Conrad; K G Ishak
Journal:  Gastroenterology       Date:  1977-05       Impact factor: 22.682

  10 in total
  1 in total

1.  Chronic non-A, non-B hepatitis in drug addicts--a follow-up study.

Authors:  R Wejstål; J Lindberg; P Lundin; B G Hansson; G Norkrans
Journal:  Infection       Date:  1988 May-Jun       Impact factor: 3.553

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.